Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_assertion type Assertion NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_head.
- NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_assertion description "[RI-HER2 was significantly more frequent in tumors with two or more recurrences (40.7% versus 15.8%, P = 0.010) and in those with carcinoma in situ (CIS) (35.4% versus 15.9%, P = 0.029).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_provenance.
- NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_assertion evidence source_evidence_literature NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_provenance.
- NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_assertion SIO_000772 15351620 NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_provenance.
- NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_assertion wasDerivedFrom befree-20150227 NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_provenance.
- NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_assertion wasGeneratedBy ECO_0000203 NP378730.RASXfuniDhmIeY5IobnvKON53FkygNkbnRYilNGZbRG3Q130_provenance.